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journals were compared using descriptive and compara-
tive chi-squared statistics.
RESULTS: 4,036 advertisements were identiﬁed from all
issues in three General and three MC journals with 194
unique advertisements evaluated for potential outcomes
messages. General and MC journals had QoL messages
included in 36.0% and 41.7% of advertisements (p <
0.005) and pharmacoeconomic messages in 7.3% and
9.0% of advertisements (p = 0.08), respectively. MC jour-
nals had more advertisements detailing pharmaceutical
expenditure savings (p = 0.01) and listing speciﬁc costs 
(p = 0.001). Trends for increased implicit QoL (p = 0.07)
and QoL references (p = 0.08) in advertisements were
found in MC journals.
CONCLUSIONS: Leading journals contain large
numbers of QoL advertisements, with MC having signif-
icantly more than General journals. MC journals are 
also more speciﬁc as to the details of the cost data,
however very few advertisements contain these messages.
Increased detail in both QoL and pharmacoeconomic
advertisements will help improve communication of this
timely data.
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OBJECTIVE: To perform a systematic review of the 
literature pertaining to the efﬁcacy of amlodipine
monotherapy in reducing systolic blood pressure (SBP) in
a variety of patient subgroups. The sixth report of the
Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC
VI) recommends diuretics or long-acting dihydropyridine
calcium channel blockers (CCBs) for the treatment of 
isolated systolic hypertension (ISH). Amlodipine is the
most commonly prescribed CCB worldwide; therefore, a
systematic review was performed to capture the impact
of amlodipine monotherapy on SBP. 
METHODS: Following a protocol that had been devel-
oped a priori, published literature in ﬁve languages was
searched from 1980 to 2001, using three electronic data-
bases and manual bibliography checks of recent review
articles and all accepted studies. Randomized controlled
trials with at least 10 patients, one treatment arm of
amlodipine monotherapy, minimum treatment duration
of 8 weeks, reporting baseline and endpoint BP, and pres-
ence of baseline hypertension (deﬁned as SBP ≥140mm
Hg, diastolic blood pressure (DBP) ≥90mmHg, or both)
were accepted for this systematic review.
RESULTS: A total of 696 citations were reviewed, of
which 85 met all inclusion criteria. Comparable treatment
arms were pooled, and weighted means of efﬁcacy results
were calculated. In the amlodipine monotherapy arms,
representing over 5,000 patients treated with the drug,
amlodipine reduced SBP by an average of 17.5mmHg
from baseline (an estimated 13.3mmHg more than
placebo). The effect of amlodipine in reducing SBP was
even more marked in elderly patients (24.1mmHg mean
reduction), black patients (23.9mmHg mean reduction),
and patients with ISH (25.9mmHg mean reduction),
although the number of studies investigating these special
populations was small. 
CONCLUSION: Amlodipine is effective for reducing
SBP. Long-term trials are needed to correlate SBP reduc-
tion with clinical outcomes.
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OBJECTIVES: To quantify the incidence of major
adverse events (AE) occurring in hospital or within 30
days after surgery in patients undergoing coronary artery
bypass grafting (CABG), and identify risk factors for
these AEs. 
METHODS: A systematic review and analysis of studies
published in English since 1990. Studies of isolated 
standard CABG reporting post-operative incidence of
myocardial infarction (MI), stroke, GI bleeding, renal
failure, or death in hospital or within 30 days, were 
eligible. The incidence of these events was calculated
overall, and for selected patient groups deﬁned by: all
elective CABG vs. mixed (elective and urgent/emergency
CABG); mean ejection fraction (EF) <50% vs. >50%;
mean age <60 years vs. >60 years; primary CABG only
vs. some patients with reoperations; RCTs vs. cohort
studies; single center vs. multicenter studies. Odds ratios
of selected AEs were computed according to group risk
factors.
RESULTS: 176 studies (205,717 patients) met all inclu-
sion criteria. The average incidence of major AEs occur-
ring in-hospital was: death -1.7% (range 0%–6.6%),
non-fatal MI—2.4% (range 0%–13.9%), non-fatal
stroke—1.3% (range 0%–3.2%), GI bleeding—1.5%
(range 0.7%–2.7%), and renal failure requiring dialysis—
0.8% (range 0%–6.2%). Thirty-day mortality was 2.1%
(range 0%–7.7%). Subset analyses revealed interesting
differences in overall mortality and MI incidence by
groups with all elective vs. mixed CABG, by study design,
mean age, primary CABG vs. some patients with re-
operation, and by number of study sites. Meta-analyses
of odds ratios suggest that old age (>70 years); female
gender; low EF; history of stroke, MI, or heart surgery;
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and presence of diabetes or hypertension are all as-
sociated with increased 30-day mortality after CABG. 
CONCLUSION: The incidence of major adverse events
in CABG patients varies widely across different studies
and patient populations. This heterogeneity must be con-
trolled when using the literature to benchmark safety.
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Current data are limited regarding the effects of statins in
the naturalistic setting of clinical practice.
OBJECTIVES: This study sought to determine the effects
of statins on the lipid proﬁle and target LDL-cholesterol
(LDL-C) attainment in this setting. 
METHODS: Patients newly initiated on atorvastatin, 
ﬂuvastatin, pravastatin, or simvastatin from 1/99 to 6/99
were retrospectively identiﬁed from a southeastern U.S.
health plan database. A parallel design incorporated four
study arms based on the statin prescribed. Exclusion 
criteria included statin therapy in the prior 6 months, less
than 90 days of statin therapy, switching of statin, use of
combination dyslipidemia therapy, or non-continuous
enrollment in the health plan. Changes in lipid subfrac-
tions and attainment of LDL-C goal based on NCEP ATP
II guidelines were evaluated with OLS and logistic regres-
sion techniques utilizing clinically relevant covariates.
RESULTS: A total of 2,429 patients (age = 62 ± 13 years,
47.8% male) were identiﬁed. Comorbidities included
73% hypertension, 24% diabetes, and 34% atheroscle-
rotic vascular disease. Median duration of statin therapy
was 19.4 months. Patients receiving atorvastatin had sig-
niﬁcantly greater mean absolute (and percentage) reduc-
tions in LDL-C and triglycerides compared to the other
statins in both the unadjusted and adjusted results (all 
p < 0.05 vs. atorvastatin). Differences in HDL-cholesterol
(HDL-C) were small, however, a statistically signiﬁcant
increase was observed with simvastatin compared to 
atorvastatin (p < 0.05). Also, a signiﬁcantly greater per-
centage (unadjusted, adjusted) of patients reached their
NCEP LDL-C goal on atorvastatin (74.0%, 73.0%) com-
pared with ﬂuvastatin (52.0%, 51.0%), pravastatin
(58.3%, 56.4%) and simvastatin (69.0%, 69.4%), and
atorvastatin patients reached goal faster than the other
statins (median: 184 days vs. 215–357 days, all p < 0.05
vs. atorvastatin). 
CONCLUSION: Patients prescribed atorvastatin had 
statistically signiﬁcant improvements in LDL-C and
triglycerides, though not in HDL-C, compared to those
prescribed other statins. In addition, atorvastatin patients
attained LDL-C goal more often and in a shorter 
timeframe.
PCV4
TRENDS IN THE ATTAINMENT OF
CHOLESTEROL TREATMENT GOALS: EVIDENCE
FROM MANAGED CARE
Menzin J1, Brown J1, Friedman M1, Saperia G2, Boulanger L1,
Tran M3
1Boston Health Economics, Waltham, MA, USA; 2Fallon Clinic,
Worcester, MA, USA; 3Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The beneﬁts of aggressive lipid-lowering
(L-L) therapy among patients with an elevated risk of
coronary heart disease (CHD) are well established, but
longitudinal data from clinical practice are limited. Our
objective was to assess trends in the rate of cholesterol
goal attainment (based on NCEP criteria) among moder-
ate- and high-risk patients in a managed care setting. 
METHODS: A retrospective cohort design was employed
using linked pharmacy claims, medical claims, and clini-
cal laboratory data from members of a Northeastern US
group model HMO. The study cohort included patients
55+ years of age who were newly treated with L-L drug
therapy between 1995 and 1998, had an LDL-C value
over 160mg/dL within 90 days prior to treatment, and
had no history of CHD but at least one CHD risk factor
other than age. The duration of follow-up was 1 year.
RESULTS: A total of 1044 patients were identiﬁed. The
average age was 68 years and 41% were male. The mean
baseline LDL-C level was 197mg/dL. Most patients
(86%) began treatment with a statin, and adherence
(evaluated by “covered days”) averaged 61%. The mean
decline in LDL-C was 25%. Target LDL-C levels were
reached by 34% of this population. The rate of LDL-C
goal attainment increased from 18% in the 1995 cohort
to 46% in the 1998 cohort. The likelihood of reaching
goal was positively associated with cohort year (P < 0.01),
male gender (P = 0.05), and beginning treatment with a
statin (P = 0.04) and negatively associated with initial
LDL-C level (P < 0.01). Age and the number of risk
factors were not associated with goal attainment.
CONCLUSIONS: In this primary prevention population,
cholesterol management improved substantially over
time. Nonetheless, most patients still did not achieve their
target LDL-C levels, indicating that further research is
required to identify steps for increasing the effectiveness
of cholesterol treatment.
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OBJECTIVES: Warfarin anticoagulation has been shown
to effectively decrease the rate of thromboembolism (TE),
with an associated increased rate of bleeding. Maximiz-
ing the beneﬁt and minimizing the risk depends on 
maintaining patients in a narrow therapeutic range for
prothrombin time (measured as INR); increased percent-
